Cargando…

The Adherence to Infusible Biologic Therapies in Inflammatory Bowel Disease Patients during the COVID-19 Pandemic: Is It Really a Problem?

Detalles Bibliográficos
Autores principales:	Barberio, Brigida, Zingone, Fabiana, Bertani, Lorenzo, Savarino, Edoardo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	by the AGA Institute 2021
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7367016/ https://www.ncbi.nlm.nih.gov/pubmed/32687929 http://dx.doi.org/10.1053/j.gastro.2020.07.017

Ejemplares similares

Viral screening before initiation of biologics in patients with inflammatory bowel disease during the COVID-19 outbreak
por: Zingone, Fabiana, et al.
Publicado: (2020)

Reply to comment: Asymptomatic screening for SARS COV-2 prior to commencement of biologic therapies in patients with inflammatory bowel disease - a potentially harmful practice
por: Zingone, Fabiana, et al.
Publicado: (2020)

Should Patients With Inflammatory Bowel Disease Be Tested for Active COVID-19 Before Starting a Biological Treatment?
por: Barberio, Brigida, et al.
Publicado: (2021)

Reorganization of the functional gastrointestinal disorders unit during the SARS-CoV-2 outbreak - Practical Recommendations
por: Ghisa, Matteo, et al.
Publicado: (2020)

Hospitalisation for Drug Infusion Did Not Increase Levels of Anxiety and the Risk of Disease Relapse in Patients with Inflammatory Bowel Disease during COVID-19 Outbreak
por: Bertani, Lorenzo, et al.
Publicado: (2021)

Reply to comment: Screening for active COVID-19 infection prior to biologic therapy in IBD patients: primum non nŏcēre
por: Zingone, Fabiana, et al.
Publicado: (2020)

Azathioprine monotherapy withdrawal in inflammatory bowel diseases: A retrospective mono-centric study
por: Crepaldi, Martina, et al.
Publicado: (2023)

Incidence comparison of adverse events in patients with inflammatory bowel disease receiving different biologic agents: retrospective long-term evaluation
por: Barberio, Brigida, et al.
Publicado: (2022)

Switching from Infliximab Originator to SB2 Biosimilar in Inflammatory Bowel Diseases: A Multicentric Prospective Real-Life Study
por: Massimi, Davide, et al.
Publicado: (2021)

Perception of the COVID-19 Pandemic Among Patients With Inflammatory Bowel Disease in the Time of Telemedicine: Cross-Sectional Questionnaire Study
por: Zingone, Fabiana, et al.
Publicado: (2020)

Extraintestinal Cancers in Inflammatory Bowel Disease: A Literature Review
por: Massano, Alessandro, et al.
Publicado: (2023)

A Survey on Nutritional Knowledge in Coeliac Disease Compared to Inflammatory Bowel Diseases Patients and Healthy Subjects
por: Marsilio, Ilaria, et al.
Publicado: (2020)

No need of transforming gastroenterology units to covid units at the time of SARS-COV2 infection - a single-center analysis from northern italy
por: Zingone, Fabiana, et al.
Publicado: (2020)

Sarcopenia, severe anxiety and increased C-reactive protein are associated with severe fatigue in patients with inflammatory bowel diseases
por: Tasson, Laura, et al.
Publicado: (2021)

A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian study
por: Barberio, Brigida, et al.
Publicado: (2021)

Medical and gastroenterological education during the COVID-19 outbreak
por: Barberio, Brigida, et al.
Publicado: (2020)

Screening for active COVID-19 infection and immunization status prior to biologic therapy in IBD patients at the time of the pandemic outbreak
por: Zingone, Fabiana, et al.
Publicado: (2020)

Lack of complications in patients with eosinophilic gastrointestinal diseases during SARS-CoV-2 outbreak
por: Savarino, Edoardo, et al.
Publicado: (2020)

Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study
por: Barberio, Brigida, et al.
Publicado: (2020)

Rapid point-of-care anti-infliximab antibodies detection in clinical practice: comparison with ELISA and potential for improving therapeutic drug monitoring in IBD patients
por: Facchin, Sonia, et al.
Publicado: (2021)

The Lyon Consensus: Does It Differ From the Previous Ones?
por: Ghisa, Matteo, et al.
Publicado: (2020)

Vonoprazan Fumarate for the Treatment of Gastric Ulcers: A Short Review on Emerging Data
por: Marabotto, Elisa, et al.
Publicado: (2020)

Efficacy and safety of oral beclomethasone dipropionate and budesonide MMX versus 5-aminosalicylates or placebo in ulcerative colitis: a systematic review and meta-analysis
por: Barberio, Brigida, et al.
Publicado: (2023)

Clinical and Psychological Impact of COVID-19 Infection in Adult Patients with Eosinophilic Gastrointestinal Disorders during the SARS-CoV-2 Outbreak
por: Savarino, Edoardo Vincenzo, et al.
Publicado: (2020)

Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator
por: Cingolani, Linda, et al.
Publicado: (2021)

Good efficacy and safety of vedolizumab in Crohn’s disease and ulcerative colitis in a real-world scenario
por: Zingone, Fabiana, et al.
Publicado: (2020)

The Risk of Malignancies in Celiac Disease—A Literature Review
por: Pelizzaro, Filippo, et al.
Publicado: (2021)

COVID-19 pandemic perception in adults with celiac disease: an impulse to implement the use of telemedicine
por: Siniscalchi, Monica, et al.
Publicado: (2020)

Letter to the Editor on “Treatment Adherence and Clinical Outcomes of Patients with Inflammatory Bowel Disease Patients During the SARS-CoV-2 Pandemic”
por: Dai, Cong, et al.
Publicado: (2021)

A specific microbiota signature is associated to various degrees of ulcerative colitis as assessed by a machine learning approach
por: Barberio, Brigida, et al.
Publicado: (2022)

Serum Levels of PCSK9 Are Increased in Patients With Active Ulcerative Colitis Representing a Potential Biomarker of Disease Activity: A Cross-sectional Study
por: Marinelli, Carla, et al.
Publicado: (2022)

Noninvasive monitoring of inflammatory bowel disease in the post COVID-19 era
por: Nardone, Olga Maria, et al.
Publicado: (2020)

Faecal microbiota transplantation in Clostridioides difficile infection: real-life experience from an academic Italian hospital
por: Barberio, Brigida, et al.
Publicado: (2020)

Therapeutic Decisions in Inflammatory Bowel Disease in the SARS-Cov-2 Pandemic
por: Brain, Oliver, et al.
Publicado: (2021)

Editorial: Challenges in Inflammatory Bowel Disease: Current, Future and Unmet Needs
por: Gravina, Antonietta Gerarda, et al.
Publicado: (2022)

Inflammatory Bowel Disease Infusion Therapy Adherence in a Rural Pediatric Population
por: Hernandez Garcia, Laura R, et al.
Publicado: (2023)

Therapeutic adherence recorded in the outpatient follow-up of inflammatory bowel diseases in a referral center: Damages of COVID-19()
por: Pellegrino, Raffaele, et al.
Publicado: (2022)

Is Fibrosis Really Fibrosis?
por: Vijayakumar, Bavithra, et al.
Publicado: (2021)

Chest CT in coronavirus pandemic. Are there really age based radiological and clinical differences?
por: Borrero, Rodrigo, et al.
Publicado: (2020)

Sleep disturbance in Inflammatory Bowel Disease: prevalence and risk factors – A cross-sectional study
por: Marinelli, C., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_k8sj4r30r7h0q67a98lp1s09lj